117 related articles for article (PubMed ID: 3720782)
21. Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923).
van Rijswijk RE; Vermorken JB; Reed N; Favalli G; Mendiola C; Zanaboni F; Mangili G; Vergote I; Guastalla JP; ten Bokkel Huinink WW; Lacave AJ; Bonnefoi H; Tumulo S; Rietbroek R; Teodorovic I; Coens C; Pecorelli S
Eur J Cancer; 2003 Mar; 39(4):481-7. PubMed ID: 12751379
[TBL] [Abstract][Full Text] [Related]
22. Predictive value of serum CA125 following optimal cytoreductive surgery during weekly cisplatin induction therapy for advanced ovarian cancer.
Hempling RE; Piver MS; Natarajan N; Baker TR; Thompson JM; Hicks ML; Mettlin CJ
J Surg Oncol; 1993 Sep; 54(1):38-44. PubMed ID: 8377503
[TBL] [Abstract][Full Text] [Related]
23. The effects of chemotherapy including cisplatin on vitamin D metabolism.
Gao Y; Shimizu M; Yamada S; Ozaki Y; Aso T
Endocr J; 1993 Dec; 40(6):737-42. PubMed ID: 7951544
[TBL] [Abstract][Full Text] [Related]
24. Influence on erythropoietin levels of treatment with cisplatinum-endoxan.
Lechner W; Artner-Dworzak E; Sölder E; Sachsenmaier M; Kölle D; Moncayo H; Reitsamer R
Arch Gynecol Obstet; 1992; 252(1):49-53. PubMed ID: 1417088
[TBL] [Abstract][Full Text] [Related]
25. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
[TBL] [Abstract][Full Text] [Related]
26. Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma.
Burke TW; Gershenson DM; Morris M; Stringer CA; Levenback C; Tortolero-Luna G; Baker VV
Gynecol Oncol; 1994 Oct; 55(1):47-50. PubMed ID: 7959265
[TBL] [Abstract][Full Text] [Related]
27. [Clinical analysis of renal dysfunction in 59 patients with gynecological malignant tumor during chemotherapy].
Li N; Li XP; Wang Y; Cui H; Wang JL; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2016 Nov; 51(11):818-824. PubMed ID: 27916064
[No Abstract] [Full Text] [Related]
28. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
Hainsworth JD; Burnett LS; Jones HW; Grosh WW; Johnson DH; Greco FA
J Clin Oncol; 1990 Mar; 8(3):502-8. PubMed ID: 2407811
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy as treatment of choice in extrapulmonary undifferentiated small cell carcinomas.
Van Der Gaast A; Verwey J; Prins E; Splinter TA
Cancer; 1990 Feb; 65(3):422-4. PubMed ID: 1688727
[TBL] [Abstract][Full Text] [Related]
30. Cyclophosphamide, doxorubicin, and cisplatin combined in the treatment of advanced sarcomas.
Edmonson JH; Hahn RG; Schutt AJ; Bisel HF; Ingle JN
Med Pediatr Oncol; 1983; 11(5):319-21. PubMed ID: 6355797
[TBL] [Abstract][Full Text] [Related]
31. Use of cisplatin, doxorubicin, and cyclophosphamide to treat advanced and recurrent adenocarcinoma of the endometrium.
Hancock KC; Freedman RS; Edwards CL; Rutledge FN
Cancer Treat Rep; 1986 Jun; 70(6):789-91. PubMed ID: 3731140
[TBL] [Abstract][Full Text] [Related]
32. High-dose, brief duration, multiagent chemotherapy for metastatic breast cancer.
Lamar RE; Greco FA; Johnson DH; Murphy PB; Hainsworth JD
Cancer; 1994 Apr; 73(7):1842-8. PubMed ID: 8137208
[TBL] [Abstract][Full Text] [Related]
33. Malignant mixed mesodermal tumors of the uterus and ovary treated with cisplatin-based combination chemotherapy.
Grosh WW; Jones HW; Burnett LS; Greco FA
Gynecol Oncol; 1986 Nov; 25(3):334-9. PubMed ID: 3023205
[TBL] [Abstract][Full Text] [Related]
34. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer.
Arriagada R; Le Chevalier T; Pignon JP; Rivière A; Monnet I; Chomy P; Tuchais C; Tarayre M; Ruffié P
N Engl J Med; 1993 Dec; 329(25):1848-52. PubMed ID: 8247036
[TBL] [Abstract][Full Text] [Related]
35. Serum erythropoietin levels in gynecologic cancer patients during cisplatin combination chemotherapy.
Hasegawa I; Tanaka K
Gynecol Oncol; 1992 Jul; 46(1):65-8. PubMed ID: 1634143
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
37. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).
du Bois A; Pfisterer J; Burchardi N; Loibl S; Huober J; Wimberger P; Burges A; Stähle A; Jackisch C; Kölbl H; ;
Gynecol Oncol; 2007 Dec; 107(3):518-25. PubMed ID: 17910981
[TBL] [Abstract][Full Text] [Related]
38. Complete responses in metastatic transitional cell carcinoma of the prostate with cisplatin regimens.
Dexeus FH; Logothetis CJ; Samuels ML; Ayala AG; Hossan E
J Urol; 1987 Jan; 137(1):122-5. PubMed ID: 3795354
[TBL] [Abstract][Full Text] [Related]
39. [Combination chemotherapy of urothelial cancer with cisplatin, cyclophosphamide, doxorubicin and peplomycin: treatment of advanced cases and adjuvant chemotherapy after radical operation].
Seguchi T; Sakaguchi H; Kajikawa H; Nishioka T
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):600-5. PubMed ID: 2435245
[TBL] [Abstract][Full Text] [Related]
40. Conservative management in primary genital lymphomas: the role of chemotherapy.
Signorelli M; Maneo A; Cammarota S; Isimbaldi G; Garcia Parra R; Perego P; Maria Pogliani E; Mangioni C
Gynecol Oncol; 2007 Feb; 104(2):416-21. PubMed ID: 17049970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
